Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOTEGRAVIR Cause Product use issue? 92 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 92 reports of Product use issue have been filed in association with CABOTEGRAVIR (Apretude). This represents 1.1% of all adverse event reports for CABOTEGRAVIR.

92
Reports of Product use issue with CABOTEGRAVIR
1.1%
of all CABOTEGRAVIR reports
5
Deaths
5
Hospitalizations

How Dangerous Is Product use issue From CABOTEGRAVIR?

Of the 92 reports, 5 (5.4%) resulted in death, 5 (5.4%) required hospitalization, and 1 (1.1%) were considered life-threatening.

Is Product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOTEGRAVIR. However, 92 reports have been filed with the FAERS database.

What Other Side Effects Does CABOTEGRAVIR Cause?

Product dose omission issue (1,121) Off label use (1,049) Injection site pain (924) Viral load increased (452) Pain (399) Virologic failure (275) Pathogen resistance (270) Pyrexia (255) Product use in unapproved therapeutic environment (234) Inappropriate schedule of product administration (228)

What Other Drugs Cause Product use issue?

INFLIXIMAB (12,752) DUPILUMAB (10,575) POLYETHYLENE GLYCOL 3350 (9,432) METHOTREXATE (8,185) DICLOFENAC (8,009) RITUXIMAB (6,948) ADALIMUMAB (6,379) ETANERCEPT (6,062) TOCILIZUMAB (5,944) ABATACEPT (5,915)

Which CABOTEGRAVIR Alternatives Have Lower Product use issue Risk?

CABOTEGRAVIR vs CABOTEGRAVIR\RILPIVIRINE CABOTEGRAVIR vs CABOZANTINIB CABOTEGRAVIR vs CABOZANTINIB S-MALATE CABOTEGRAVIR vs CAFFEINE CABOTEGRAVIR vs CALASPARGASE PEGOL

Related Pages

CABOTEGRAVIR Full Profile All Product use issue Reports All Drugs Causing Product use issue CABOTEGRAVIR Demographics